Setting the Shortest Examination Time of Gastroscopy to Improve the Detection Rate of Upper Gastrointestinal Tumors

Sponsor
Changhai Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT04602299
Collaborator
(none)
2,000
2
2
14.5
1000
69.2

Study Details

Study Description

Brief Summary

This multicenter, prospective, interventional study aims to include 2000 gastroscopic procedures and investigate the relationship between procedure time and lesion detection rate in tertiary endoscopic centers in China. At the first stage, the researchers observe the actual procedure time of gastroscopies without affecting the natural behavior of endoscopists. At the second stage, a minimal time limit will be set for each procedure based on the observational results of the first stage. The primary study outcome is focal lesion detection rate. Secondary outcomes include detection rate of early upper GI cancer, biopsy rate and adverse event rate.

Condition or Disease Intervention/Treatment Phase
  • Other: Set the minimum time of gastroscopy
N/A

Detailed Description

China is a country with a heavy burden of gastric cancer and esophageal cancer. In 2015, the incidence/mortality of gastric cancer and esophageal cancer in China were 680000/500000 and 220000/200000, respectively. Gastroscopy is the most important means to detect early cancer of gastrointestinal tract. However, due to various factors, the miss rate of clinical significant lesions by gastroscopy is innegligible. Our previous research results showed that the detection rate of early gastric cancer and early esophageal cancer in China was only about 15%. This study aims to include 2000 gastroscopic procedures and investigate the relationship between procedure time and lesion detection rate in tertiary endoscopic centers in China.

At the first stage, the researchers observe the actual procedure time of gastroscopies without affecting the natural behavior of endoscopists. Then, researchers collect the data (including focal lesion detection rate, procedure time, detection rate of early upper GI cancer, biopsy rate and adverse event rate) and analyze the minimal procedure time. At the second stage, a minimal time limit will be set for each procedure. Every stage last two months, and potential correlations between lesion detection rate and procedure time will be investigated through subsequent statistical analysis.

Study Design

Study Type:
Interventional
Actual Enrollment :
2000 participants
Allocation:
Non-Randomized
Intervention Model:
Sequential Assignment
Masking:
None (Open Label)
Primary Purpose:
Screening
Official Title:
Setting the Shortest Examination Time of Gastroscopy to Improve the Detection Rate of Upper Gastrointestinal Tumors: a Multi-center, Prospective, Controlled Study
Actual Study Start Date :
Nov 1, 2020
Actual Primary Completion Date :
Dec 31, 2021
Actual Study Completion Date :
Jan 15, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Set the minimum time of gastroscopy

Other: Set the minimum time of gastroscopy
This study contains 2 stages. At the first stage, no interventions are implemented. The researchers just observe the actual procedure time of gastroscopy. At the second stage, a minimal procedure time is set based on the observational results of the first stage.

No Intervention: Observe the procedure time of gastroscopy

Outcome Measures

Primary Outcome Measures

  1. focal lesion detection rate [two months]

    number of gastroscopy procedures that detects focal lesions divided by the number of all gastroscopy procedures

Secondary Outcome Measures

  1. detection rate of high risk lesions [two months]

    number of gastroscopy procedures that detect upper GI cancers (gastric or esophageal cancer), dysplasia and intestinal metaplasia divided by the number of all gastroscopy procedures

  2. endoscopic biopsy rate [two months]

    number of gastroscopy procedures with biopsy divided by the number of all gastroscopy procedures

  3. detection rate of neoplastic lesions [two months]

    number of gastroscopy procedures that detect upper GI cancers divided by the number of all gastroscopy procedures

  4. mean (median) examination time for normal EGDs without biopsy [two months]

    mean (median) examination time for all normal EGDs without biopsy

  5. rate of procedures reaching the minimal time [two months]

    number of gastroscopy procedures that reach the minimal time divided by the number of all gastroscopy procedures

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • No history of benign and malignant tumors (including carcinoma and adenoma) of upper GI (including esophagus, stomach and duodenum)

  • undergo gastroscopy with intravenous anesthesia (or conscious sedation)

Exclusion Criteria:
  • Subjects with focal lesions detected by gastroscopy within 1 year

  • Subjects that cannot stand the gastroscopy procedure or cannot cooperate with endosccopists

  • Emergency endoscopy and therapeutic endoscopy

  • Subjects with history of esophageal or stomach surgery or endoscopic surgery

  • Pregnant

  • Subjects that taking antiplatelet or anticoagulant drugs which contradicts endoscopic biopsy

  • Subjects with other serious complications that affect the speed of gastroscopy

  • Subjects that refuse to cooperate with data collection or sign the informed consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 Changhai Hospital, Second Military Medical University Shanghai China 200433
2 Changhai Hospital Shanghai China 200433

Sponsors and Collaborators

  • Changhai Hospital

Investigators

  • Principal Investigator: Ye Gao, Changhai Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Zhaoshen Li, Director of Gastroenterology, Changhai Hospital
ClinicalTrials.gov Identifier:
NCT04602299
Other Study ID Numbers:
  • gastroscopy time
First Posted:
Oct 26, 2020
Last Update Posted:
Mar 18, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 18, 2022